利索-全球专利检索

  1. 登录
  2. 注册

搜索结果

229 条记录 (耗时 0.031 秒)

    ASSAY TO DIAGNOSE AND TREAT DISORDERS OF THE ALTERNATIVE PATHWAY OF COMPLEMENT ACTIVATION
    5.
    发明申请
    ASSAY TO DIAGNOSE AND TREAT DISORDERS OF THE ALTERNATIVE PATHWAY OF COMPLEMENT ACTIVATION 审中-公开

    公开(公告)号：US20180246082A1

    公开(公告)日：2018-08-30

    申请号：US15553826

    申请日：2016-02-29

    申请人： THE JOHNS HOPKINS UNIVERSITY

    发明人： Robert Brodsky

    IPC分类号： G01N33/50 ,  C07K16/18 ,  A61P7/00

    CPC分类号： G01N33/5091 ,  A61P7/00 ,  C07K16/18 ,  C07K2317/24 ,  C07K2317/76 ,  G01N2440/00 ,  G01N2800/22

    摘要： The present invention relates generally to the field of disorders of complement activation. More specifically, the present invention provides methods and compositions useful for diagnosing and treating atypical hemolytic uremic syndrome, antiphospholipid antibody syndrome and other disorders of the alternative pathway of complement activation. In one embodiment, a method comprises the steps of (a) incubating or contacting serum obtained from a patient suspected of having atypical hemolytic uremic syndrome (aHUS) with a glycosylphosphatidylinositol-anchored protein (GPI-AP) deficient cell line; and (b) performing a cell viability assay on the cells from step (a). In a specific embodiment, the method further comprises the step of diagnosing the patient as having aHUS based on a statistically significant increased difference of non-viable cells from the patient serum as compared to a control.

    Use of Viscoelastic Analysis for Predicting Massive Hemorrhage
    7.
    发明申请
    Use of Viscoelastic Analysis for Predicting Massive Hemorrhage 审中-公开

    公开(公告)号：US20180011116A1

    公开(公告)日：2018-01-11

    申请号：US15664565

    申请日：2017-07-31

    申请人： The Regents of the University of Colorado, a body corporate

    发明人： Michael P. Chapman

    IPC分类号： G01N33/86 ,  A61B5/02

    CPC分类号： G01N33/86 ,  A61B5/02042 ,  A61B2505/05 ,  G01N33/4905 ,  G01N2800/22 ,  G01N2800/50

    摘要： The invention provides methods for identifying a patient as likely to have an onset of massive hemorrhage. In one embodiment, the invention provides a method for identifying a patient as likely to have an onset of massive hemorrhage, the method comprising measuring at least one of first coagulation characteristic parameter reflective of a clotting time in a sample of blood of the patient, a second coagulation characteristic parameter reflective of clot formation in a sample of blood of the patient using the viscoelastic assay to obtain a second result; a third coagulation characteristic parameter reflective of clot strength in a sample of blood of the patient using the viscoelastic assay to obtain a third result; and a fourth coagulation characteristic parameter reflective of clot lysis in a sample of blood of the patient using the viscoelastic assay to obtain a fourth result; wherein, a positive for at least one of the first result, second result, third result and fourth result identifies the patient as likely to have an onset of massive hemorrhage.

    Heptadecanoic acid supplement to human diet
    9.
    发明授权
    Heptadecanoic acid supplement to human diet 有权

    公开(公告)号：US09707199B2

    公开(公告)日：2017-07-18

    申请号：US14980304

    申请日：2015-12-28

    申请人： SPAWAR SYSTEMS CENTER PACIFIC

    发明人： Stephanie Venn-Watson

    IPC分类号： A61K31/20 ,  A61K31/201 ,  A61K31/202 ,  G01N33/92

    CPC分类号： A61K31/20 ,  A61K31/201 ,  A61K31/202 ,  G01N33/92 ,  G01N2405/00 ,  G01N2800/04 ,  G01N2800/042 ,  G01N2800/22 ,  G01N2800/50

    摘要： Methods for detecting risks for and/or causes of metabolic syndrome or hyperferritinemia in accordance with several embodiments can include the step of measuring the level of heptadecanoic acid in a blood sample of a subject. The methods of several embodiments can further include the step of deeming the subject as having or being at risk of metabolic syndrome if the amount of heptadecanoic acid is below 0.4% of all fatty acids in the sera or plasma. The methods for treating metabolic syndrome or hyperferritinemia according to several embodiments can also include the step of administering a daily dose of heptadecanoic acid to a subject suffering from metabolic syndrome or hyperferritinemia for a period of time from three weeks to twenty-four weeks, wherein the minimum daily dose comprises about 3 mg per lb (or 6 mg per kg) of body weight.